After Another Look, Vadadustat (VAFSEO) Becomes the Second HIF-PHD Inhibitor Approved by the FDA

vadadustat (VAFSEO)

oral HIF-PHD enzyme inhibitor Ph. III candidate for anemia in CKD carboxylic acid class of HIF-PHD inhibitors J. Pharmacol. Exp. Ther., Oct 1, 2022 Akebia Therapeutics, Cambridge, MA

Authors:

Dennis C. Koester,

Shaima Qunies

Editors:

Rory McAtee,

Dennis X. Hu

After Another Look, Vadadustat (VAFSEO) Becomes the Second HIF-PHD Inhibitor Approved by the FDA

vadadustat (VAFSEO)

Other molecules you may be interested in